SCHEMBL1065877

SCHEMBL1065877

Nc1ccc(-c2nc3ccccc3o2)cc1N

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.68
RAB9A P51151 11/20 0.68
MEN1 O00255 5/20 0.68
KMT2A Q03164 5/20 0.68
ATM Q13315 1/20 0.68
ALDH1A1 P00352 11/20 0.61
KDM4E B2RXH2 10/20 0.61
HPGD P15428 10/20 0.61
SMN1; SMN2 Q16637 9/20 0.61
MAPT P10636 6/20 0.61
TP53 P04637 5/20 0.61
GAA P10253 4/20 0.61
NFKB1 P19838 2/20 0.61
STAT1 P42224 2/20 0.61
NFKB2 Q00653 2/20 0.61
RELA Q04206 2/20 0.61
GFER P55789 2/20 0.61
LMNA P02545 1/20 0.61
HSD17B10 Q99714 6/20 0.58
GLA P06280 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3320297 0.87 NPC1 (0.64) NPC1RAB9AMEN1KMT2AATM
SCHEMBL7107181 0.86 NPC1 (0.62) NPC1RAB9AMEN1KMT2AATM
SCHEMBL2493904 0.86 NPC1 (0.64) NPC1RAB9AMEN1KMT2AATM
SCHEMBL11646171 0.86 NPC1 (0.64) NPC1RAB9AMEN1KMT2AATM
SCHEMBL31631311 0.86 NPC1 (0.64) NPC1RAB9AMEN1KMT2AATM
SCHEMBL12997099 0.86 NPC1 (0.62) NPC1RAB9AMEN1KMT2AATM
SCHEMBL2174585 0.82 NPC1 (0.66) NPC1RAB9AMEN1KMT2AATM
SCHEMBL759091 0.82 NPC1 (0.77) NPC1RAB9AMEN1KMT2AATM
SCHEMBL10271102 0.82 NPC1 (0.57) NPC1RAB9AMEN1KMT2AATM
SCHEMBL31170 0.82 NPC1 (0.81) NPC1RAB9AMEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
WO-2010137349-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS 住友化学株式会社 (JP) 2010-12-02 WO disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 US disclosed
EP-1663953-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-06-07 EP disclosed
WO-2005030705-A9 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2006-04-20 WO disclosed
WO-2005030705-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed
WO-2005030704-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed
WO-2005030704-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132459-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 NPC1 1197/4885RAB9A 2909/4885MEN1 2635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.